Thiotepa

Generic Name: Thiotepa

Brand Names: Tepadina, Thiotepa Riemser

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₃PS

CAS Number: 52-24-4

Unique Ingredient Identifier: 905Z5W3GKH

Background: N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...

Indication: ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions: Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion

Associated Therapies: -

Clinical Trials

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Phase 2

Recruiting

Conditions: Acute Biphenotypic Leukemia
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Hematopoietic and Lymphoid Cell Neoplasm
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Myelodysplastic Syndrome With Excess Blasts

Interventions: Biological: Dilanubicel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Thiotepa
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation
Other: Laboratory Biomarker Analysis
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Procedure: Bone Marrow Biopsy
Procedure: Multigated Acquisition Scan
Procedure: Electrocardiography
Procedure: Computed Tomography

First Posted Date: 2018-01-16

Last Posted Date: 2024-11-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT03399773

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma

Phase 2

Completed

Conditions: Malignant Lymphoma

Interventions: Drug: Thiotepa

First Posted Date: 2017-11-17

Last Posted Date: 2024-07-09

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 50

Registration Number: NCT03346096

Locations: 🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel

Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Melphalan
Drug: Thiotepa
Drug: Fludarabine

First Posted Date: 2017-11-14

Last Posted Date: 2024-07-05

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT03342196

Locations: 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Procedure: Haploidentical Bone Marrow Transplantation
Drug: Hydroxyurea
Drug: Rabbit-ATG
Drug: Thiotepa
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total Body Irradiation
Drug: Mesna

First Posted Date: 2017-08-28

Last Posted Date: 2023-12-28

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 80

Registration Number: NCT03263559

Locations: 🇺🇸
Texas Children's Hospital (Baylor), Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Nicklaus Children's Hospital/University of Miami Children's Hospital, Miami, Florida, United States

and more 29 locations

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction

Phase 2

Terminated

Conditions: Very High Risk Neuroblastoma

Interventions: Radiation: mIBG
Drug: Thiotepa
Drug: Topotecan
Procedure: Autologous stem cell transplant

First Posted Date: 2017-05-24

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 34

Registration Number: NCT03165292

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇦🇹
St. Anna Kinderspital GmbH, Vienna, Austria
🇮🇹
Fondazione IRCCS Istituto nazionaleTumori, Milano, Italy

and more 6 locations

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3

Active, not recruiting

Conditions: Ganglioneuroblastoma
Neuroblastoma

First Posted Date: 2017-04-25

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 724

Registration Number: NCT03126916

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 158 locations

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

Phase 2

Conditions: High Risk Neuroblastoma

Interventions: Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Etoposide
Radiation: 131I-MIBG
Drug: Thiotepa
Drug: Melphalan

First Posted Date: 2017-02-23

Last Posted Date: 2018-09-18

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 40

Registration Number: NCT03061656

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

Not Applicable

Completed

Conditions: Hematologic Malignancy

Interventions: Drug: melphalan
Drug: fludarabine
Drug: thiotepa
Drug: Cyclophosphamide
Drug: Mesna
Drug: Mycophenolate Mofetil
Drug: Filgrastim
Drug: Tacrolimus

First Posted Date: 2016-08-26

Last Posted Date: 2024-12-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 44

Registration Number: NCT02880293

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Phase 2

Recruiting

Conditions: Retinoblastoma

Interventions: Radiation: Orbital irradiation
Other: Observation
Drug: Etoposide
Drug: Vincristine
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Thiotepa
Procedure: Cytapheresis
Procedure: Peripheral bood stem cell transplantation

First Posted Date: 2016-08-17

Last Posted Date: 2024-05-31

Lead Sponsor: Institut Curie

Target Recruit Count: 185

Registration Number: NCT02870907

Locations: 🇫🇷
Chr Felix Guyon, Saint-Denis, La Réunion, France
🇫🇷
Hopital Nord Chu Amiens, Amiens, France
🇫🇷
Chu Angers, Angers, France

and more 24 locations

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Phase 1

Completed

Conditions: Sickle Cell Disease
Graft Versus Host Disease

Interventions: Drug: Diphenhydramine
Drug: Acetaminophen
Drug: Methylprednisolone
Drug: Meperidine
Drug: Alemtuzumab
Drug: Thymoglobulin
Drug: Fludarabine
Drug: Melphalan
Drug: Thiotepa
Drug: Cyclosporine
Drug: Tacrolimus
Drug: Methotrexate
Drug: Abatacept
Procedure: Marrow infusion
Drug: Sirolimus
Drug: Mycophenolate Mofetil

First Posted Date: 2016-08-16

Last Posted Date: 2024-06-13

Lead Sponsor: Monica Bhatia

Target Recruit Count: 24

Registration Number: NCT02867800

Locations: 🇺🇸
North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States
🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy